ASCO receives $11M from PCORI to study oral drug dosing strategies

Teclistamab extends OS, deepens remissions in landmark trial published in NEJM and presented at ASCO

Patients with relapsed multiple myeloma treated with the immunotherapy teclistamab (TECVALI) lived significantly longer and remained in remission far longer than those receiving standard therapies, according to results from a major international phase III clinical trial published in The New England Journal of Medicine and presented at the 2026 American Society of Clinical Oncology annual meeting.

May 29, 2026

Vol.52 No.21

Collaborative work behind the scenes makes cancer breakthroughs possible

When we talk about breakthroughs in cancer research, most focus on the moment of discovery: a new therapy, a promising trial result, or a headline-grabbing study.

May 08, 2026

Vol.52 No.18

By Annaliese Daniels

In Brief

Neal Meropol named PI of ASCO’s TAPUR study

Neal J. Meropol was named principal investigator of the American Society of Clinical Oncology’s Targeted Agent and Profiling Utilization Registry study.

February 27, 2026

Vol.52 No.08

Clinical Roundup

Microplastics are discovered in prostate tumors, NYU researchers present at ASCO GU

Small fragments of plastic were found in nine out of 10 patients with prostate cancer, and in higher levels inside tumors than in nearby noncancerous tissue, according to a study led by NYU Langone Health, its Perlmutter Cancer Center, and its Center for the Investigation of Environmental Hazards.

February 27, 2026

Vol.52 No.08

In Brief

ASCO special awards recipients include: John Carpten, Eduardo Vilar-Sanchez, Enrique Soto, Nancy Davidson, Sharon Giordano

ASCO and Conquer Cancer, the ASCO Foundation, will present its highest honors to a group of researchers, educators, patient advocates, and global leaders for their career-defining excellence and tremendous contributions to cancer progress around the globe.

January 23, 2026

Vol.52 No.03

Should I have a drink tonight?
In anticipation of the first holiday season since the surgeon general’s report on alcohol and cancer, we ask experts to weigh in

New Year’s Eve approaches, and with it, a chance to turn a new leaf with renewed energy, to reflect on—or perhaps, in the case of 2025, bemoan—the events of the year, and, most importantly, to celebrate.

December 19, 2025

Vol.51 No.46

By Jacquelyn Cobb

ASCO receives $11M from PCORI to study oral drug dosing strategies

YOU MAY BE INTERESTED IN

Teclistamab extends OS, deepens remissions in landmark trial published in NEJM and presented at ASCO

Collaborative work behind the scenes makes cancer breakthroughs possible

Neal Meropol named PI of ASCO’s TAPUR study

Microplastics are discovered in prostate tumors, NYU researchers present at ASCO GU

ASCO special awards recipients include: John Carpten, Eduardo Vilar-Sanchez, Enrique Soto, Nancy Davidson, Sharon Giordano

Should I have a drink tonight?
In anticipation of the first holiday season since the surgeon general’s report on alcohol and cancer, we ask experts to weigh in

Renew today!

Subscriber content

Never miss an issue!

Login

ASCO receives $11M from PCORI to study oral drug dosing strategies

YOU MAY BE INTERESTED IN

Teclistamab extends OS, deepens remissions in landmark trial published in NEJM and presented at ASCO

Collaborative work behind the scenes makes cancer breakthroughs possible

Neal Meropol named PI of ASCO’s TAPUR study

Microplastics are discovered in prostate tumors, NYU researchers present at ASCO GU

ASCO special awards recipients include: John Carpten, Eduardo Vilar-Sanchez, Enrique Soto, Nancy Davidson, Sharon Giordano

Should I have a drink tonight?In anticipation of the first holiday season since the surgeon general’s report on alcohol and cancer, we ask experts to weigh in

Never miss an issue!

Login

Should I have a drink tonight?
In anticipation of the first holiday season since the surgeon general’s report on alcohol and cancer, we ask experts to weigh in